Medclair
CARE FOR FUTURE

Medclair AB (publ)
INTERIM REPORT Q3 2026

We work for a sustainable use of nitrous oxide while simultaneously contributing to significantly reducing the carbon footprint.

Medclair. From Exposure to Control

Q3

Medclair

From Exposure to Control

Proven technology for safer operations

Medclair is a Swedish technology company with proprietary and proven solutions for measuring, capturing and destroying nitrous oxide (N_2O). Our technology enables customers to identify and control gas-related risks, improve workplace safety and reduce climate impact.

With documented results and international experience, Medclair has established a strong position in safe and efficient nitrous oxide management.

Our solutions serve Healthcare, Dental and Industry. A growing installed base and an expanding product and service offering create opportunities for recurring revenues, additional sales and continued international growth.

OUR FOCUS



DETECT

Identify gas exposure through measurement and monitoring.



CAPTURE

Safely capture nitrous oxide directly at the source.



MANAGE

Eliminate emissions and enable long-term control through proven technology and service.

Interim report Q3 2026

The quarter in brief

Order intake
20.9 SEK m

Net sales
13.5 SEK m

Book-to-Bill Ratio
1.55

THIRD QUARTER IN BRIEF
1 JULY – 30 SEPTEMBER 2026

- Order intake amounted to SEK 20.9 million (14.9)
- Net sales amounted to SEK 13.5 million (10.5)
- Profit before depreciation and financial items SEK amounted 0.7 million (1.8)
- Profit after tax amounted to SEK -0.8 million (0.3)
- Earnings per share after tax amounted to SEK -0.008 (0.004)

THE REPORTING PERIOD IN BRIEF
1 JANUARY – 30 SEPTEMBER 2026

- Order intake amounted to SEK 62.1 million (49.6)
- Net sales amounted to SEK 46.0 million (42.0)
- Profit before depreciation and financial items amounted to SEK 7.0 million (11.8)
- Profit after tax amounted to SEK 2.6 million (6.8)
- Earnings per share after tax amounted to SEK 0.03 (0.08)

Key figures (TSEK)	Q3 2026	Q3 2025	9M 2026	9M 2025	FY 2025
Net sales	13,481	10,499	45,999	41,966	52,084
Order intake	20,900	14,900	62,100	49,600	73,200
Order backlog	26,400	–	26,400	–	–
Book-to-Bill Ratio	1.55	1.42	1.35	1.18	1.41
EBITDA	714	1,782	6,985	11,811	11,171
Earnings per share (SEK)	-0.008	0.004	0.03	0.08	0.06
Intangible fixed assets	35,062	33,531	35,062	33,531	33,817
Cash and cash equivalents	9,675	1,789	9,675	1,789	5,739
Cash flow for the period	-9,195	533	3,936	-794	3,156
Equity	77,984	55,876	77,984	55,876	53,686
Total assets	88,426	64,157	88,426	64,157	60,677
Equity ratio (%)	88%	87%	88%	87%	88%
Current ratio (%)	460%	302%	460%	302%	306%
Number of shares at end of period	91,647,057	82,492,057	91,647,057	82,492,057	82,492,057
Number of employees at end of period	19	15	19	15	16

700 installations – a growing asset with significant earning potential

Medclair continues to grow. During the third quarter, order intake increased by 40 percent and net sales by 28 percent. The result remained positive and amounted to 0.7 MSEK (1.8), despite the significant investments currently being made to enable continued expansion. But behind the quarter's figures lies something that I consider at least as important for understanding the company's long-term potential: our growing installed base.

At the end of the quarter, Medclair had approximately 700 installations of varying size and complexity across 250 customers in 20 countries. This is the result of several years of international expansion and a strategic asset whose significance extends far beyond the initial sale.

An installation is not the end of a deal. It is the beginning of the next one

Each installation creates opportunities for revenue from service, repairs, consumables, and supplementary equipment. A customer who starts with one installation can, over time, become a significantly larger customer. Furthermore, with a growing product range, the opportunities to develop each customer relationship increase.

This is where a vital part of our future earning capacity lies.

We are scaling up earnings from our installed base

During the third quarter, we conducted a review of our business model, with a particular focus on how we design our offerings and charge for service, repairs, and warranties.

We have now begun implementing a more structured commercial model. Already during the first quarter of this work, we have signed new agreements corresponding to approximately SEK 900,000 in annual recurring revenue.

The total revenue base of a recurring nature thus amounts to approximately SEK 3.6 million on an annual basis. These are revenues that contribute to the continuity of the business and create a foundation for further growth.

In addition, we estimate that a further approximately SEK 1 million in annual revenue can be activated from already installed equipment.

The important thing is that the SEK 3.6 million we generate today only represents a fraction of the earning opportunities in our installed base. By gradually increasing the proportion of customers with service and maintenance agreements, developing the sale of consumables, and offering supplementary solutions, we can increase the revenue per installation over time.

Our ambition is clear: each new installation should not only contribute to this year's sales, but also strengthen future years' revenues.

New technology creates new opportunities for value growth

At the same time, we are facing a significant technology shift. Our new photocatalytic technology makes it possible to develop smaller, more flexible, and scalable products.

This means more than a technical advancement. By reducing the size of the products and increasing flexibility, we can reach areas of application where today's solutions have limitations. This creates the conditions for new customer groups and a broader market within Healthcare, Dental, and Industry.

For Medclair, the technology shift entails two opportunities for value creation: reaching more customers and increasing earnings from the ones we already have.

> **This is where a vital part of our future earning capacity lies.**

An installation is not the end of a deal. It is the beginning of the next.

A broader product offering gives us the opportunity to sell more solutions to existing customers, while the scalability of the technology could eventually open up new business and revenue models.

During the second half of 2027, we expect to introduce the first commercial products based on the new technology, with Dental as the first segment. Moreover, already during 2027, we will supplement our existing offering with new products.

We have previously estimated the total addressable market for our technology at approximately SEK 17 billion. The technology shift gives us the conditions to gradually reach a larger part of this potential through more areas of application and a broader commercial offering.

Today's business builds tomorrow's earning capacity

Our strong order intake is an important part of this development. Every new deal contributes not only to upcoming sales. When new equipment is delivered and installed, the base that can generate service revenue, sales of consumables, and cross-selling for many years to come also grows. Upgrades and supplementary deliveries simultaneously contribute to developing the value of our existing customer relationships.

During the third quarter, order intake increased by 40 percent to SEK 20.9 million and net sales by 28 percent to SEK 13.5 million. During the first nine months of the year, order intake amounted to SEK 62.1 million, an increase of 25 percent.

With a book-to-bill ratio of 1.55, order intake exceeded the quarter's net sales by a good margin. To clarify how today's business creates conditions for future sales, we are now also introducing the order backlog as a key performance indicator. At the end of the quarter, it amounted to SEK 26.4 million. As the orders are delivered, they will generate revenue and, where they relate to new installations, further strengthen our installed base.

We continue to grow across all three business areas. During the quarter, we have strengthened our position within the industrial segment in the UK and France. Meanwhile, within Healthcare, expansion continues in Germany, where the collaboration with Nippon Gases is driving a growing presence in maternity care.

The strong order intake has also continued during the beginning of the fourth quarter. We therefore reiterate our previous assessment that net sales for the full year 2026 will exceed the 2025 level by a good margin.

With a growing order backlog, a strengthened international market position, and an expanding installed base, we enter 2027 with significantly better conditions for continued growth. Our assessment is that the positive revenue development will continue in the coming years, supported by both increased sales volumes and a gradually growing share of recurring revenue.

My ambition is clear: we will translate these opportunities into a significantly larger business, with growing revenues, an increasingly strong recurring revenue base, and long-term increased profitability.



Jonas Lundh
CEO

Financial Performance and Position

The Group
The Group's income statement for the period January–September 2026 comprises the parent company Medclair AB and the subsidiary Medclair Sweden AB. The comparative period is January–September 2025. The merger of the parent company and the subsidiary was completed on 21 October 2026, after the end of the reporting period.

Order intake and order backlog
Order intake during the third quarter increased by 40 percent to MSEK 20.9 (14.9). For the period January–September, order intake amounted to MSEK 62.1 (49.6), an increase of 25 percent. The book-to-bill ratio amounted to 1.55 (1.42) for the quarter and 1.35 (1.18) for the period. Order intake thereby exceeded deliveries by a good margin.

At the end of the period, the order backlog amounted to MSEK 26.4. The majority is expected to be delivered during the fourth quarter of 2026 and the first quarter of 2027.

Revenue and results
Net sales in the third quarter increased by 28 percent to MSEK 13.5 (10.5). For the period January–September, net sales amounted to MSEK 46.0 (42.0), an increase of 10 percent. The gross margin was 65 percent (64) for the quarter and 66 percent (68) for the period.

Operating expenses have increased as the company has built up its organisation and international sales capacity. Personnel costs for the quarter amounted to MSEK 4.4 (2.9), and the number of employees at the end of the period was 19 (15). Other external costs amounted to MSEK 5.2 (2.9). The increase mainly relates to sales consultants in new and existing markets, including Denmark and the UK, as well as staffing in production. Premises costs have also increased.

Profit before depreciation and financial items (EBITDA) amounted to MSEK 0.7 (1.8) for the quarter and MSEK 7.0 (11.8) for the period. The lower result is mainly explained by costs for building up sales and the organisation increasing faster than net sales. These investments aim to increase sales in coming periods.

Operating profit amounted to MSEK -0.7 (0.3) for the quarter and MSEK 2.6 (7.3) for the period. Profit for the period amounted to MSEK -0.8 (0.3) for the quarter and MSEK 2.6 (6.8) for the period. Earnings per share amounted to SEK -0.008 (0.004) for the quarter and SEK 0.03 (0.08) for the period.

During the third quarter, the subsidiary transferred patents to the parent company as part of the merger. The capital gain of MSEK 31.0 in the subsidiary is intra-group and has been eliminated in the consolidated accounts. It therefore does not affect the Group's result.

Investments and depreciation
The Group's investments in tangible, intangible and financial non-current assets amounted to MSEK 1.6 (0.8) for the quarter and MSEK 5.0 (2.4) for the period. Investments mainly relate to capitalised development expenditure of MSEK 4.0 for the period, linked to the development of new and existing products. Depreciation and amortisation amounted to MSEK 1.3 (1.2) for the quarter and MSEK 3.9 (3.8) for the period, of which MSEK 2.7 (2.7) relates to goodwill for the period.

Assets
The Group's non-current assets amounted to MSEK 40.4 (39.1) as of 30 September 2026. Of these, MSEK 14.9 (18.5) relates to goodwill attributable to the acquisition of Medclair Sweden AB, MSEK 17.7 (12.6) to capitalised development expenditure and MSEK 2.6 (2.4) to patents.

The Group's current assets excluding cash and cash equivalents amounted to MSEK 38.4 (23.2). The increase is mainly explained by trade receivables increasing to MSEK 23.8 (3.6) as a result of high invoicing towards the end of the quarter. Inventories amounted to MSEK 6.1 (9.4).

Equity
The Group's equity amounted to MSEK 53.7 (49.0) at the beginning of the financial year and MSEK 78.0 (55.9) at the end of the period. The increase is explained by the directed share issue carried out during the first quarter, which provided the company with MSEK 21.7, and by the profit for the period. The equity ratio was 88 percent (87). At the most recent year-end, the share capital amounted to SEK 8,249,206, divided into 82,492,057 shares, each with a quota value of SEK 0.10. Following the share issue, the share capital amounts to SEK 9,164,706, divided into 91,647,057 shares.

Cash flow and financial position
Cash flow from operating activities before changes in working capital amounted to MSEK 0.6 (1.6) for the quarter and MSEK 6.5 (10.5) for the period. After changes in working capital, cash flow from operating activities amounted to MSEK -7.6 (1.3) for the quarter and MSEK -12.8 (1.6) for the period. The negative cash flow is mainly explained by increased trade receivables, i.e. sales that have been invoiced but not yet paid.

Cash flow from investing activities amounted to MSEK -5.0 (-2.4) for the period. Cash flow from financing activities amounted to MSEK 21.7 (0.0) and relates to the share issue. Cash flow for the period amounted to MSEK -9.2 (0.5) for the quarter and MSEK 3.9 (-0.8) for the period.

Cash and cash equivalents amounted to MSEK 9.7 (1.8) at the end of the period. Current liabilities amounted to MSEK 10.4 (8.3) and the current ratio was 460 percent (302). The Group has no interest-bearing liabilities.

Parent company

The parent company's net sales for January–September amounted to MSEK 0.0 (0.0). Operating profit amounted to MSEK -2.4 (-1.0) and profit for the period to MSEK -2.4 (-0.9). The equity ratio was 96 percent (99). Cash and cash equivalents amounted to MSEK 9.0 (1.3) at the end of the period.


During the third quarter, the parent company acquired patents from the subsidiary Medclair Sweden AB for MSEK 33.6. The purchase price was settled by offsetting an intra-group receivable of MSEK 25.4. The remaining amount was recorded as an intra-group liability, of which approximately MSEK 5 was paid during the quarter. The acquisition is intra-group and does not affect the Group's result or cash flow.

Significant events during the third quarter

1 Jul	Medclair adds a new recycling customer in France
2 Jul	SUEZ highlights Medclair's technology in French project
3 Jul	Medclair clarifies framework agreement with Folktandvården – contract value 6 MSEK
9 Jul	Medclair merges subsidiary and updates patent valuation – expected to generate a positive one-off effect of approximately MSEK 30
13 Jul	Medclair secures exclusive framework agreement with French purchasing center Resah
11 Aug	Medclair expands internationally - Singapore and New Zealand
20 Aug	Medclair receives a new order worth approximately 12 MSEK in the UK
1 Sep	Medclair accelerates its expansion in Germany
16 Sep	British study shows clear benefit of Medclair's technology

Significant events after the end of the reporting period

21 Oct	Medclair has completed the merger with the subsidiary Medclair Sweden AB
28 Oct	Medclair's installed base creates new business – British operator invests an additional SEK 6.2 million
2 Nov	UK recognition strengthens Medclair's position ahead of continued expansion within the NHS



Outlook for the group

Medclair sees significant long-term growth opportunities within Healthcare, Dental, and Industry. The total addressable market for the company's technology has been estimated at approximately SEK 17 billion. Demand is driven by increased requirements for the working environment, reduced climate impact, and safe nitrous oxide management. Medclair's current market presence encompasses only a limited part of this potential.

With proven technology, an established international presence, and strategic partnerships, Medclair is well-positioned to gradually increase its market penetration. Continued geographical expansion and a broader product offering are expected to create the conditions for a significantly larger customer base and increased sales volumes.

The new photocatalytic technology is expected to further strengthen growth opportunities through smaller, more flexible, and scalable solutions that open up new areas of application, customer groups, and business models. The first commercial products are planned to be introduced during the second half of 2027, with Dental as the first segment.

At the same time, the growing installed base creates opportunities for increased recurring revenues and cross-selling. The combination of more customers, a broader offering, and increased earnings per customer is expected to gradually strengthen the scalability and profitability of the business.

Overall, Medclair assesses that the company's market position, technological development, and commercial strategy create the conditions for a significantly larger international business with sustained growth, strengthened profitability, and improved cash generation.

Risks and uncertainties

Customer and credit risk
The Group's customers are mainly public healthcare providers, distributors and industrial companies. Long decision-making processes and public procurement may affect the timing of orders and deliveries. Individual large orders and customers may account for a significant share of net sales and trade receivables, which entails a risk of delayed payments and credit losses.

Liquidity risk
Working capital requirements vary with the timing of invoicing and deliveries during the year. Delays in customer payments may affect the company's cash and cash equivalents. The company continuously monitors liquidity and trade receivables.

Currency risk
A significant share of sales is denominated in EUR and GBP, while part of the costs are in SEK. Exchange rate fluctuations may therefore affect net sales, margins and results.

Supplier and production risk
Production disruptions at suppliers, delays or delivery failures may affect the company's ability to deliver in accordance with the order backlog.

Patents and intellectual property
The Group holds a number of key patents. This entails a risk of infringement, which could lead to lengthy and costly legal disputes.

Development risk
The company invests in the development of new products and technologies. There is a risk that development takes longer or becomes more costly than planned, or that products do not achieve the expected market acceptance.

Personnel and key individuals
The company's development depends on competent employees and consultants. Unwanted staff turnover or the loss of key individuals may disrupt planned activities.

External environment
The uncertain global environment may entail risks related to the supply of raw materials and purchase prices.

Note

This information is such that Medclair AB is obliged to disclose under the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the CEO, on November 5, 2026, at 08:00 CET. This report has not been subject to review by the company's auditors.

Stockholm, November 5, 2026

Medclair AB
Jonas Lundh, CEO

Accounting Principles

This report has been prepared in accordance with the Swedish Annual Accounts Act (ÅRL) and BFNAR 2012:1 (K3). The accounting principles applied are the same as those used in the most recent annual report.

For further information, please contact:

Jonas Lundh, CEO, Medclair AB,
Phone: +46 76 – 193 90 90, jonas.lundh@medclair.com

MEDCLAIR'S CLIMATE BENEFIT Q3 2026

Almost half of Stockholm's annual emissions


Climate benefit from the equipment Medclair has delivered for capturing nitrous oxide (N_2O), which would otherwise leak into the atmosphere.

Medclair's climate benefit

727,000 tonnes CO_2

City of Stockholm, total emissions 2023

~1.49 million tonnes CO_2e



The chart shows the volume of nitrous oxide that Medclair's installed base as of Q3 2026 (30 September) prevents from reaching the atmosphere, converted to tonnes of CO_2e per year.

Medclair's climate benefit (727,000 tonnes)

Remaining emissions in the City of Stockholm

Source Stockholm: Miljöbarometern, City of Stockholm — 1.5 tonnes CO_2e/inhabitant (2023, transport, energy use and waste) × approx. 990,000 inhabitants.

The Group's Income Statement

KSEK	Jul–Sep 2026 3 mon	Jul–Sep 2025 3 mon	Jan–Sep 2026 9 mon	Jan–Sep 2025 9 mon	Jan–Dec 2025 12 mon
Net sales	13,481	10,499	45,999	41,966	52,084
Own work capitalised	1,446	811	3,995	2,659	3,981
Other operating income	112	90	492	248	517
Goods for resale	-4,694	-3,742	-15,535	-13,336	-18,024
Other external costs	-5,195	-2,943	-13,962	-10,453	-13,774
Personnel costs	-4,436	-2,933	-14,004	-9,273	-13,613
EBITDA	**714**	**1,782**	**6,985**	**11,811**	**11,171**
Amortization, depreciation and impairment of tangible and intangible fixed assets	-1,310	-1,247	-3,883	-3,825	-5,005
Other operating expenses	-153	-205	-477	-725	-1,028
Operating profit	**-749**	**330**	**2,625**	**7,261**	**5,138**
Financial items	-1	17	-54	-419	-485
Income tax	-	-	-	-	-
Net profit for the period	**-750**	**347**	**2,571**	**6,842**	**4,653**

The Group´s Balance Sheet

KSEK	30 Sep 2026	30 Sep 2025	31 Dec 2025
Non-current assets			
Intangible non-current assets	35,062	33,531	33,817
Tangible non-current assets	5,164	5,585	5,448
Financial non-current assets	128	-	-
Total non-current assets	**40,354**	**39,116**	**39,265**
Current assets			
Inventories, etc.	6,075	9,421	5,946
Accounts receivable	23,758	3,629	4,118
Current tax receivables	-	190	29
Other receivables	417	2,669	1,560
Prepaid expenses and accrued income	8,147	7,343	4,020
Cash and bank	9,675	1,789	5,739
Total current assets	**48,072**	**25,041**	**21,412**
Total assets	**88,426**	**64,157**	**60,677**
Equity	**77,984**	**55,876**	**53,686**
Current liabilities			
Accounts payable	5,103	3,874	3,198
Current tax liabilities	46	-	-
Other liabilities	668	340	1,429
Accrued expenses and deferred income	4,625	4,067	2,364
Total current liabilities	**10,442**	**8,281**	**6,991**
Total equity and liabilities	**88,426**	**64,157**	**60,677**

The Group´s Equity

KSEK	30 Sep 2026	30 Sep 2025	31 Dec 2025
Statement of changes in equity			
Opening equity	53,686	49,034	49,034
Share issue	21,727	-	-
Net profit for the period	2,571	6,842	4,653
Total equity	**77,984**	**55,876**	**53,686**

The Group´s Cash Flow

KSEK	Jul–Sep 2026 3 mon	Jul–Sep 2025 3 mon	Jan–Sep 2026 9 mon	Jan–Sep 2025 9 mon	Jan–Dec 2025 12 mon
Profit after financial items	-750	347	2,571	6,842	4,653
Adjustment for non-cash items	1,349	1,222	3,959	3,644	5,062
Cash flow before changes in working capital	**599**	**1,569**	**6,530**	**10,486**	**9,715**
Change in working capital	-8,152	-225	-19,348	-8,845	-2,717
Cash flow from operating activities	**-7,553**	**1,344**	**-12,818**	**1,641**	**6,998**
Investing activities	**-1,642**	**-811**	**-4,973**	**-2,435**	**-3,842**
Financing activities	**-**	**-**	**21,727**	**-**	**-**
Total cash flow	**-9,195**	**533**	**3,936**	**-794**	**3,156**
Cash and cash equivalents at the beginning of the period	18,870	1,256	5,739	2,583	2,583
Cash and cash equivalents at the end of the period	**9,675**	**1,789**	**9,675**	**1,789**	**5,739**

Parent Company Income Statement

KSEK	Jul–Sep 2026 3 mon	Jul–Sep 2025 3 mon	Jan–Sep 2026 9 mon	Jan–Sep 2025 9 mon	Jan–Dec 2025 12 mon
Other operating income	10	7	36	28	51
Other external expenses	-430	-184	-1,056	-516	-806
Personnel costs	-177	-177	-537	-535	-713
Operating profit before depreciation and financial items	**-597**	**-354**	**-1,557**	**-1,023**	**-1,468**
Depreciation and amortisation	-841		-841		
Other operating expenses	-	-	-	-	-
Operating profit	**-1,438**	**-354**	**-2,398**	**-1,023**	**-1,468**
Financial items	-1	21	13	159	256
Income tax	**-**	**-**	**-**	**-**	**-**
Net profit for the period	**-1,439**	**-333**	**-2,385**	**-864**	**-1,212**

Parent Company Balance Sheet

KSEK	30 Sep 2026	30 Sep 2025	31 Dec 2025
Non-current assets			
Intangible non-current assets	32,784	-	-
Shares in group companies	46,504	46,504	46,504
Total non-current assets	**79,288**	**46,504**	**46,504**
Current assets			
Receivables from group companies	-	16,667	16,167
Current tax assets	22	30	
Other receivables	32	1,644	1,317
Prepaid expenses and accrued income	42	94	74
Cash and bank balances	8,992	1,330	1,637
Total current assets	**9,088**	**19,765**	**19,195**
Total assets	**88,376**	**66,269**	**65,699**
Equity	**84,812**	**65,818**	**65,470**
Current liabilities			
Accounts payable	90	70	-
Liabilities to group companies	3,096	-	-
Other liabilities	-	2	-
Accrued expenses and deferred income	378	379	229
Total current liabilities	**3,564**	**451**	**229**
Total equity and liabilities	**88,376**	**66,269**	**65,699**

Parent Company Equity

KSEK	30 Sep 2026	30 Sep 2025	31 Dec 2025
Changes in Equity			
Opening Equity	65,470	66,682	66,682
New share issue	21,727	-	-
Profit for the period	-2,385	-864	-1,212
Total equity	**84,812**	**65,818**	**65,470**

Parent Company Cash Flow

KSEK	Jul–Sep 2026 3 mon	Jul–Sep 2025 3 mon	Jan–Sep 2026 9 mon	Jan–Sep 2025 9 mon	Jan–Dec 2025 12 mon
Profit after financial items	-1,439	-334	-2,385	-864	-1,212
Non-cash items	841	-2	841	-30	-
Cash flow before changes in working capital	**-598**	**-336**	**-1,544**	**-894**	**-1,212**
Changes in working capital	-4,908	777	-12,828	-1,070	-445
Cash flow from operating activities	**-5,506**	**441**	**-14,372**	**-1,964**	**-1,657**
Investing activities	**-**	**-**	**-**	**1,055**	**1,055**
Financing activities	**-**	**-**	**21,727**	**-**	**-**
Total cash flow	**-5,506**	**441**	**7,355**	**-909**	**-602**
Cash and cash equivalents at the beginning of the period	14,498	889	1,637	2,239	2,239
Cash and cash equivalents at the end of the period	**8,992**	**1,330**	**8,992**	**1,330**	**1,637**

Glossary: definitions of key figures

Net sales
Operating revenue from goods sold and services provided during the period, net of discounts and VAT.

EBITDA
Operating profit before depreciation, amortisation, impairment, other operating expenses and financial items. Measures operational profitability.

Equity ratio (%)
Equity expressed as a percentage of total assets at the end of the period. Indicates the company's long-term financial stability.

Current ratio (%)
Current assets divided by current liabilities, expressed as a percentage. Measures the company's ability to meet short-term obligations.

Cash flow for the period
The net change in cash and cash equivalents during the period, comprising operating, investing, and financing activities.

Number of shares at end of period
Total number of registered and outstanding shares on the balance sheet date.

Earnings per share
Profit or loss for the period divided by the weighted average number of shares outstanding during the period.

Order intake
The total monetary value of all received and confirmed customer orders during the period. Indicates underlying market demand and future revenue growth.

Order backlog
The value of received and confirmed customer orders, as well as remaining contracted volumes under framework agreements, not yet delivered or invoiced at the end of the period.

Book-to-Bill Ratio
The ratio of order intake to net sales during the period (Order intake / Net sales). A ratio above 1.0 indicates that demand exceeds current deliveries, signaling business expansion

Number of employees at end of period
Number of employees in the Group at the balance sheet date.

Gross margin (%)
Net sales less goods for resale, as a percentage of net sales.

Equity and shareholder structure

Equity
At the beginning of the financial year, the Group's equity amounted to MSEK 53.7 (49.0). At the end of the third quarter, equity amounted to MSEK 78.0 (55.9). The increase is explained by the directed share issue carried out during the first quarter, which provided the company with MSEK 21.7 after issue costs, and by the profit for the period of MSEK 2.6. The equity ratio was 88 percent (87).

Share capital and number of shares
At the end of the previous financial year, the share capital amounted to SEK 8,249,206, divided into 82,492,057 shares, each with a quota value of SEK 0.10. Following the directed share issue, the share capital amounts to SEK 9,164,706, divided into 91,647,057 shares, each with a quota value of SEK 0.10.

Warrants and employee stock option programmes
As of 30 September 2026, the company had no outstanding warrants or employee stock option programmes.

Ownership structure
The table below shows the company's largest shareholders as of 30 September 2026.

Owner	Shares	%
AVANZA Pension	16,436,974	17.94%
Eiffel Investment Group	10,047,000	10.96%
Bäck Family*	8,000,000	8.73%
Johansson Family	5,840,000	6.37%
Nordnet Pension	4,690,301	5.12%
Piroska Forkman	3,491,000	3.81%
Baljeu Family	2,806,000	3.06%
Crafoord Capital	1,700,000	1.85%
Jerker Sundling	1,492,062	1.63%
Peter Håkansson	1,303,000	1.42%
Szabo Family	949,000	1.04%
Total number of shares	91,647,057	

The proportion of shares held via Nordnet and Avanza is relatively high, as some shareholders own shares through pension solutions.

* The holding is estimated based on the owner's information.

Upcoming reporting dates

Year-end report 2026	2027-02-23
Interim report Q1 2027	2027-04-27
Interim report Q2 2027	2027-08-17
Interim report Q3 2027	2027-10-26

© 2026 Medclair AB (publ.)
Registration number: 556691-3728

Medclair is a member of Swecare and Nordic Centre for Sustainable Healthcare.

www.medclair.com

FOLLOW US